Skip to Content

Accelerate Diagnostics, Inc.

Securities Class Action

  • Date:
  • 11/16/2022
  • Company Name:
  • Accelerate Diagnostics, Inc.
  • Stock Symbol:
  • AXDX
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Accelerate Diagnostics, Inc. (“Accelerate Diagnostics” or the “Company”) (NASDAQ: AXDX) on behalf of Accelerate Diagnostics stockholders. Our investigation concerns whether Accelerate Diagnostics has violated the federal securities laws and/or engaged in other unlawful business practices.

After the market closed on October 21, 2022, Accelerate Diagnostics, Inc. disclosed receiving a request from the U.S. Food and Drug Administration for the company to immediately discontinue marketing and distribution of its Accelerate Arc system and related BC Kit for a particular diagnostic use.
 
Previously, Accelerate Diagnostics had been marketing the Accelerate Arc products as Class I devices, exempting them from 510(k) clearance requirements. Recently, the FDA informed the company that marketing the products in the U.S. requires 510(k) clearance.
 
Shares of Accelerate Diagnostics, Inc. stock dropped approximately 9% in premarket trading and were down more than 40% in intraday trading on October 24, 2022.
 
If you purchased or otherwise acquired Accelerate Diagnostics shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Accelerate Diagnostics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: